Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Brown JR, Eichhorst B, Hillmen P, Jurczak W, et al. N Engl J Med 2022 Dec 13. doi: 10.1056/NEJMoa2211582.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Brown JR, Eichhorst B, Hillmen P, Jurczak W, et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 2022 Dec 13. doi: 10.1056/NEJMoa2211582.
PMID: 36511784